Whole Genome Sequencing for cancer diagnostics clinically validated
Scientific research has demonstrated that Whole Genome Sequencing (WGS) is at least as reliable as routine diagnostic procedures. Clinical Molecular Biologist in Pathology Paul Roepman of Hartwig Medical Foundation in collaboration with national experts in the field recently published this research in The Journal of Molecular Diagnostics.
Measured reliably with a single WGS test
Together with academic partners Antoni van Leeuwenhoek – Netherlands Cancer Institute, Erasmus MC, Radboudumc, UMC Utrecht and Amsterdam UMC, they have shown that the results of WGS for detection of simple mutations, gene amplifications and deletions, and gene fusions are very similar to those of routine diagnostic procedures, with similarly high sensitivity. More complex tumor characteristics such as microsatellite instability (MSI), tumor mutational load and the presence of HPV can also be measured very reliably with a single WGS test.
Independence of the research
As part of the validation of WGS for routine clinical use, results and outcomes were compared one-to-one with the findings of routine diagnostic tests. The academic partners helped to conduct the routine tests for this comparison to ensure the independence of the research. The researchers demonstrated the validity of the various results. For all types of abnormalities, the results of WGS when using frozen samples with sufficient tumor cells (20%) were at least equal to the results obtained with regular diagnostic tests.
WIDE: prospective study to examine the utility of WGS in routine healthcare practice
This clinical validation is an important requirement for adopting new technology in routine healthcare. Meanwhile, researchers are also conducting a prospective study called WIDE to examine the utility of WGS in routine healthcare practice. WIDE stands for WGS Implementation in standard Diagnostic tests for Every cancer patient. The interim analysis of this study has been completed and confirms the clinical validity of WGS, but also revealed that WGS identifies more actionable biomarkers and thus provides additional treatment options for the patient.
- Paper in The Journal of Molecular Diagnostics: Clinical validation of Whole Genome Sequencing for cancer diagnostics
- Interview with Kim Monkhorst, pathologist at the Netherlands Cancer Institute, on the interim results of WIDE: Whole Genome Sequencing feasible in clinical practice
- Video for physicians and pathologists: OncoAct (in Dutch)
- More information about the comprehensive DNA test: OncoAct.nl
Whole Genome Sequencing feasible in clinical practice
Interim WIDE analysis gives researchers more confidence in a positive outcome. On 21 September 2020, Dr. Kim Monkhorst, who is a …
SAGE: New algorithm for analysis of tumor DNA reveals mutations previously not found
At Hartwig we “analyse sequenced tumor DNA”. This is something we try to continuously improve. These analyses are shared with …
In the media: Rarity – Personalised cancer treatment – fact not fiction
Imagine a world in which each person’s cancer is treated with a personalised, targeted medical treatment regimen. A world in …
By using WGS, we took a step forward in molecular diagnostics in our department from the analysis of less than 100 genes to approximately 20,000 genes per patient. This provides an enormous amount of valuable information, not only for the patient of today, but also for the patient of the future.